Bronchial neoplasm

This global study is testing whether adding the experimental drug olomorasib to standard immunotherapy and chemotherapy can help people with a specific genetic subtype of advanced non-small cell lung cancer (KRAS G12C mutation). About 1,264 participants will receive either the ne…

This study tests a new drug, firmonertinib, against two standard treatments for people with advanced non-small-cell lung cancer that has certain rare genetic changes (EGFR PACC mutations). About 480 participants who have not had prior treatment for advanced disease will be random…

This study is for people with a specific type of lung cancer (EGFR-mutant) that has spread to other parts of the body after they finished a previous treatment (osimertinib). The goal is to see if combining osimertinib with chemotherapy can help control the cancer for longer. Abou…

This study tests two experimental drugs, elironrasib and daraxonrasib, given alone or together, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drugs are safe and can shrink or control the cancer. About 534 adults with lung,…

This phase 2 trial tests a personalized therapy called LN-145, made from a patient's own tumor-fighting immune cells. Researchers take a sample of the tumor, grow the immune cells in a lab, and then infuse them back into the patient after a short course of chemotherapy. The goal …

This study tests a new treatment called IOV-4001 for people with advanced melanoma or non-small-cell lung cancer. The treatment uses a patient's own tumor-fighting immune cells, which are collected, genetically modified to remove a 'brake' called PD-1, and then infused back after…

This study tests a new drug called repotrectinib in people with advanced solid tumors that have certain gene changes (ALK, ROS1, or NTRK). The trial has two parts: first, finding a safe dose, and second, seeing how well the drug shrinks tumors. About 500 adults with advanced canc…

This phase 2 trial tests whether combining the immunotherapy drug cemiplimab with either chemotherapy or targeted radiation (SBRT) before surgery can eliminate or shrink non-small cell lung cancer more effectively. About 112 people with stage IB to III (N2) lung cancer will recei…

This study looks at two standard treatments for early-stage lung cancer: surgery and a precise type of radiation called stereotactic radiotherapy. About 670 veterans with stage I non-small cell lung cancer will take part. The goal is to see which treatment leads to longer surviva…